製品番号: HY-N0060B

(E)-Ferulic acid

(別名: (E)-Coniferic acid; 3-メトキシけい皮酸)

1 Cited Publications

カスタマーレビュー

Based on 1 publication(s) in Google Scholar

(E)-Ferulic acid is an isomer of ferulic acid, an aromatic compound abundant in plant cell walls. (E)-Ferulic acid causes phosphorylation of β-catenin (β-catenin), leading to proteasome degradation, increasing the expression of pro-apoptotic factor Bax and reducing pro-apoptotic factor Expression of the survival factor survivin. (E)-Ferulic acid can effectively remove reactive oxygen species (ROS) and inhibit lipid peroxidation. (E)-Ferulic acid exerts antiproliferative and antimigratory effects in the human lung cancer cell line H1299.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.82%
CAS 番号: 537-98-4
分子式: C₁₀H₁₀O₄
分子量:194.19

保管条件:

Store at room temperature 3 years.

In solvent -80°C, 2 years , -20°C, 1 year

(E)-Ferulic acid 構造式

CAS 番号: 537-98-4

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
化学情報
Publications (1)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target^[1]

Bax	Microbial Metabolite

Bcl-2 Family アイソフォーム固有の製品をすべて表示 :

Endogenous Metabolite アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>100 μM Compound: 13	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 21696954]
A549	IC₅₀	2.6 mM Compound: Ferulic acid	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by FMCA assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by FMCA assay	[PMID: 27162124]
A549	IC₅₀	3.1 mM Compound: Ferulic acid	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 27162124]
A549	IC₅₀	3.2 mM Compound: Ferulic acid	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by luminescence-based ATP assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by luminescence-based ATP assay	[PMID: 27162124]
A549	IC₅₀	>10 μM Compound: 7	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 27700070]
BT-549	IC₅₀	>10 μM Compound: 7	Cytotoxicity against human BT549 cells after 48 hrs by SRB assay Cytotoxicity against human BT549 cells after 48 hrs by SRB assay	[PMID: 27700070]
BT-549	IC₅₀	1.2 μM Compound: 1	Antiproliferative activity against human BT549 cells after 24 hrs by MTT assay Antiproliferative activity against human BT549 cells after 24 hrs by MTT assay	[PMID: 29144746]
BV-2	IC₅₀	>50 μM Compound: 7	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 27700070]
BV-2	EC₅₀	>10 μM Compound: 2	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced microglial activation after 24 hrs by Griess reagent based assay Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced microglial activation after 24 hrs by Griess reagent based assay	[PMID: 29407994]
C2BBe1	IC₅₀	>200 μM Compound: 2; FA	Cytotoxicity against human C2BBe1 cells assessed as reduction in cell proliferation after 24 hrs by sulforhodamine B assay Cytotoxicity against human C2BBe1 cells assessed as reduction in cell proliferation after 24 hrs by sulforhodamine B assay	[PMID: 27290693]
C2BBe1	IC₅₀	>200 μM Compound: 2; FA	Cytotoxicity against human C2BBe1 cells assessed as reduction in cell proliferation after 48 hrs by sulforhodamine B assay Cytotoxicity against human C2BBe1 cells assessed as reduction in cell proliferation after 48 hrs by sulforhodamine B assay	[PMID: 27290693]
C2BBe1	IC₅₀	>200 μM Compound: 2; FA	Cytotoxicity against human C2BBe1 cells assessed as reduction in cell proliferation after 72 hrs by sulforhodamine B assay Cytotoxicity against human C2BBe1 cells assessed as reduction in cell proliferation after 72 hrs by sulforhodamine B assay	[PMID: 27290693]
C2BBe1	IC₅₀	>200 μM Compound: 2; FA	Cytotoxicity against human C2BBe1 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay Cytotoxicity against human C2BBe1 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay	[PMID: 27290693]
HT-22	EC₅₀	>10 μM Compound: 2	Neuroprotective activity against IAA-induced ischemia in mouse HT22 cells assessed as increase in cell viability cotreated with IAA for 2 hrs followed by IAA wash out measured after 24 hrs by MTT assay Neuroprotective activity against IAA-induced ischemia in mouse HT22 cells assessed as increase in cell viability cotreated with IAA for 2 hrs followed by IAA wash out measured after 24 hrs by MTT assay	[PMID: 29407994]
K562	IC₅₀	>1000 μM Compound: Ferulic acid	Cytotoxicity against human K562 cells after 5 days by XTT assay Cytotoxicity against human K562 cells after 5 days by XTT assay	[PMID: 18076140]
LoVo	IC₅₀	95 μM Compound: 13	Cytotoxicity against human LoVo cells after 72 hrs by MTT assay Cytotoxicity against human LoVo cells after 72 hrs by MTT assay	[PMID: 21696954]
MCF7	IC₅₀	0.36 μM Compound: FerA	Antiproliferative activity against human MCF7 cells assessed as cell viability after 24 hrs Antiproliferative activity against human MCF7 cells assessed as cell viability after 24 hrs	[PMID: 33139111]
MDA-MB-231	IC₅₀	0.5 μM Compound: 1	Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 29144746]
MDA-MB-231	IC₅₀	15 μM Compound: FerA	Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs	[PMID: 33139111]
MT4	CC₅₀	>10 μM Compound: 8	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 3 days by CytoTox-Glo assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 3 days by CytoTox-Glo assay	[PMID: 26756779]
MT4	EC₅₀	>10 μM Compound: 8	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in viral replication measured on day 3 post infection by luciferase reporter gene assay Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in viral replication measured on day 3 post infection by luciferase reporter gene assay	[PMID: 26756779]
Neutrophil	IC₅₀	200 μM Compound: 2; FA	Inhibition of phorbol myristate acetate-induced human neutrophils oxidative burst assessed as reduction in luminol oxidation preincubated for 5 mins followed by PMA addition measured after 15 mins by chemiluminescence assay Inhibition of phorbol myristate acetate-induced human neutrophils oxidative burst assessed as reduction in luminol oxidation preincubated for 5 mins followed by PMA addition measured after 15 mins by chemiluminescence assay	[PMID: 27290693]
PC-3	IC₅₀	>100 μM Compound: 13	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 21696954]
RAW264.7	IC₅₀	>100 μM Compound: 12	Antiinflammatory activity in mouse RAW264.7 cells assessed as decrease in LPS-induced NO production after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as decrease in LPS-induced NO production after 24 hrs by Griess assay	[PMID: 25666824]
SH-SY5Y	IC₅₀	11.82 μM Compound: ferulic acid	Antioxidant activity in human SH-SY5Y cells assessed as reduction in H2O2-induced reactive oxygen species formation measured after 24 hrs by DCFH-DA probe based fluorescence assay Antioxidant activity in human SH-SY5Y cells assessed as reduction in H2O2-induced reactive oxygen species formation measured after 24 hrs by DCFH-DA probe based fluorescence assay	[PMID: 28282613]
SK-MEL-2	IC₅₀	>10 μM Compound: 7	Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay	[PMID: 27700070]
SK-MEL-28	IC₅₀	>100 μM Compound: 13	Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay	[PMID: 21696954]
SK-OV-3	IC₅₀	>10 μM Compound: 7	Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay	[PMID: 27700070]
TT	IC₅₀	150 μM Compound: Ferulic acid	Cytotoxicity against human TT cells by trypan blue dye-based assay Cytotoxicity against human TT cells by trypan blue dye-based assay	[PMID: 31336310]
U-373MG ATCC	IC₅₀	>100 μM Compound: 13	Cytotoxicity against human U373 cells after 72 hrs by MTT assay Cytotoxicity against human U373 cells after 72 hrs by MTT assay	[PMID: 21696954]
WiDr	IC₅₀	>200 μM Compound: 2; FA	Cytotoxicity against human WiDr cells assessed as reduction in cell proliferation after 24 hrs by sulforhodamine B assay Cytotoxicity against human WiDr cells assessed as reduction in cell proliferation after 24 hrs by sulforhodamine B assay	[PMID: 27290693]
WiDr	IC₅₀	>200 μM Compound: 2; FA	Cytotoxicity against human WiDr cells assessed as reduction in cell proliferation after 48 hrs by sulforhodamine B assay Cytotoxicity against human WiDr cells assessed as reduction in cell proliferation after 48 hrs by sulforhodamine B assay	[PMID: 27290693]
WiDr	IC₅₀	>200 μM Compound: 2; FA	Cytotoxicity against human WiDr cells assessed as reduction in cell proliferation after 72 hrs by sulforhodamine B assay Cytotoxicity against human WiDr cells assessed as reduction in cell proliferation after 72 hrs by sulforhodamine B assay	[PMID: 27290693]
WiDr	IC₅₀	>200 μM Compound: 2; FA	Cytotoxicity against human WiDr cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay Cytotoxicity against human WiDr cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay	[PMID: 27290693]

体外実験

(E)-Ferulic acid (0.03-0.6 mM, 24 h, 48 h) has anti-proliferation and anti-migration effects in human lung cancer cell line H1299 ^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

H1299
Concentration:

0.03-0.6 mM
Incubation Time:

24 h, 48 h
Result:

Low dose had no significant cytotoxic effect, but cytotoxicity was observed with 0.3 and 0.6 mM for 48 h.

Apoptosis Analysis^[1]

Cell Line:

H1299
Concentration:

0.03-0.6 mM
Incubation Time:

48 h
Result:

Caused the arrest of the cell cycle at G0/G1 and a decrease in the percentage of the G2/M phase. And induced a significant increase in apoptotic populations. with 0.6 mM

Cell Migration Assay ^[1]

Cell Line:

H1299
Concentration:

0.03-0.6 mM
Incubation Time:

16 h, (48 h)
Result:

Inhibited cell migration and invasion. by reducing the activity of MMP‑2 and MMP‑9 and increased β-catenin phosphorylation at Thr41/Ser45 but did not affect β-catenin protein levels.

体内実験

(E)-Ferulic acid (100 mg/kg, gavage, once a day for 21 days) can reduce the effect of liver and kidney toxicity and oxidative stress posed by tamoxifen in rats. ^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male Wister Albino Rat model^[2]
Dosage:

100 mg/kg
Administration:

i.g, once a day for 21 days
Result:

Decreased tamoxifen-induced elevated enzyme activities of AST, ALT, and ALP and ameliorated the decrease in the hepatic enzyme activities.

化学情報

CAS 番号 537-98-4
性状 Solid
分子量 194.19
分子式 C₁₀H₁₀O₄
Color White to light yellow
SMILES

O=C(O)/C=C/C1=CC=C(O)C(OC)=C1
別名

(E)-Coniferic acid; 3-メトキシけい皮酸
Structure Classification
- Phenylpropanoids
- Simple Phenylpropanols
- Phenols
- Monophenols
Initial Source
- Plants
- other families
- Endogenous metabolite
- Human Gut Microbiota Metabolites
- Microorganisms
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Store at room temperature 3 years

In solvent	-80°C	2 years
	-20°C	1 year

Publications (1)

All

Sort by:

Journal Impact Factor

Adv Sci (Weinh)

Targeting Fibrotic Scarring by Mechanoregulation of Il11ra1+/Itga11+ Fibroblast Patterning Promotes Axon Growth after Spinal Cord Injury. [Abstract]

2025 Sep 9:e13476. PMID: 40923460

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (514.97 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

5.1497 mL

25.7485 mL

51.4970 mL

5 mM

1.0299 mL

5.1497 mL

10.2994 mL

10 mM

0.5150 mL

2.5749 mL

5.1497 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (12.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (12.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (12.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (277 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Fong Y, et al. Inhibitory effect of trans-ferulic acid on proliferation and migration of human lung cancer cells accompanied with increased endogenous reactive oxygen species and β-catenin instability. Chin Med. 2016 Oct 1;11:45. [Content Brief]

[2]. Ogbuta A A, et al. Protective Effects of Trans-Ferulic acid on Tamoxifen Induced Heptatic and Renal Oxidative Stress in Male Wister Albino Rat. Journal of Applied Sciences and Environmental Management, 2023, 27(8): 1727-1732.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	5.1497 mL	25.7485 mL	51.4970 mL	128.7425 mL
	5 mM	1.0299 mL	5.1497 mL	10.2994 mL	25.7485 mL
	10 mM	0.5150 mL	2.5749 mL	5.1497 mL	12.8743 mL
	15 mM	0.3433 mL	1.7166 mL	3.4331 mL	8.5828 mL
	20 mM	0.2575 mL	1.2874 mL	2.5749 mL	6.4371 mL
	25 mM	0.2060 mL	1.0299 mL	2.0599 mL	5.1497 mL
	30 mM	0.1717 mL	0.8583 mL	1.7166 mL	4.2914 mL
	40 mM	0.1287 mL	0.6437 mL	1.2874 mL	3.2186 mL
	50 mM	0.1030 mL	0.5150 mL	1.0299 mL	2.5749 mL
	60 mM	0.0858 mL	0.4291 mL	0.8583 mL	2.1457 mL
	80 mM	0.0644 mL	0.3219 mL	0.6437 mL	1.6093 mL
	100 mM	0.0515 mL	0.2575 mL	0.5150 mL	1.2874 mL

Keywords

(E)-Ferulic acid

1 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

(E)-Ferulic acid

Apoptosis Compound Library

Metabolism/Protease Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Medicine Food Homology Compound Library

Phenols Library

Cytoskeleton Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Neuroprotective Compound Library

Anti-Lung Cancer Compound Library

Gut Microbial Metabolite Library

Microbial Metabolite Library

Anti-Obesity Compound Library

Mitochondria-Targeted Compound Library

Transcription Factor-Targeted Library

Food-Sourced Compound Library

Anti-Cancer Natural Product Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Osteogenesis Compound Library

Highly Selective Activators Library

Cell Death Library

Extracellular Vesicles (EVs) Compound Library

Multi-Target Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Chinese Baijiu Compound Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Mass Spectrometry Natural Product Library

MedChemExpress（MCE）の使用を引用している文献 (E)-Ferulic acid

Bcl-2 Family アイソフォーム固有の製品をすべて表示

Endogenous Metabolite アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (1)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

(E)-Ferulic acid 関連分類

HY-N0060B 関連分類